img-spleen-targeted-neoantigen-dna-vaccine-personalized-immunotherapy-hepatocellular-carcinoma-1920x640
Literature - Publication Review

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Researchers investigated how a spleen-targeted DNA vaccine, delivered via RBC-hitchhiked nanoparticles, effectively induced robust neoantigen specific T cell responses in hepatocellular carcinoma (HCC). This approach not only inhibited tumor growth, but also showed potential for complete tumor regression when combined with anti-PD-1 therapy, offering a promising strategy for personalized immunotherapy in HCC.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Download Literature - Publication Review